BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28609020)

  • 1. Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis.
    Costentin CE; Decaens T; Laurent A; Nault JC; Paule B; Letoublon C; Luciani A; Calderaro J; Adam R; Bricault I; Amaddeo G; Cherqui D; Mallat A; Samuel D; Duvoux C; Ganne-Carrié N; Roudot-Thoraval F; Vibert E
    Liver Int; 2017 Dec; 37(12):1869-1876. PubMed ID: 28609020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib.
    de la Torre MA; Buades-Mateu J; de la Rosa PA; Lué A; Bustamante FJ; Serrano MT; Testillano M; Lorente S; Arenas JI; Gil C; Iñarrairaegui M; Sangro B
    Liver Int; 2016 Aug; 36(8):1206-12. PubMed ID: 26910784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching.
    Kaplan DE; Mehta R; D'Addeo K; Gade TP; Taddei TH
    J Vasc Interv Radiol; 2018 Apr; 29(4):540-549.e4. PubMed ID: 29477619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
    Cho Y; Lee JH; Lee DH; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS
    Oncotarget; 2017 Jul; 8(29):47555-47564. PubMed ID: 28548930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
    Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
    Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study.
    Barbier L; Fuks D; Pessaux P; Muscari F; Le Treut YP; Faivre S; Belghiti J
    Ann Surg Oncol; 2013 Oct; 20(11):3603-9. PubMed ID: 23715965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study.
    Wada Y; Takami Y; Matsushima H; Tateishi M; Ryu T; Yoshitomi M; Matsumura T; Saitsu H
    Intern Med; 2018 May; 57(10):1345-1353. PubMed ID: 29279513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
    J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
    Sohn W; Paik YH; Cho JY; Lim HY; Ahn JM; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    J Hepatol; 2015 May; 62(5):1112-21. PubMed ID: 25514557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
    Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
    Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib as an adjuvant therapy for resectable hepatocellular carcinoma: A single center experience.
    Antoniou EA; Margonis GA; Amini N; Anastasiou M; Angelou A; Kim Y; Kouraklis G
    J BUON; 2016; 21(5):1189-1194. PubMed ID: 27837622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Sarpel U; Spivack JH; Berger Y; Heskel M; Aycart SN; Sweeney R; Edwards MP; Labow DM; Kim E
    HPB (Oxford); 2016 May; 18(5):411-8. PubMed ID: 27154804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
    Yoon EL; Yeon JE; Ko E; Lee HJ; Je JH; Yoo YJ; Kang SH; Suh SJ; Kim JH; Seo YS; Yim HJ; Byun KS
    J Korean Med Sci; 2017 Feb; 32(2):212-220. PubMed ID: 28049231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
    Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
    Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting.
    Kondo M; Morimoto M; Ishii T; Nozaki A; Fukuda H; Numata K; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Shibuya A; Okuse C; Suzuki M; Sakamaki K; Morita S; Maeda S; Tanaka K
    J Dig Dis; 2015 Mar; 16(3):143-51. PubMed ID: 25495751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy.
    Yoshimoto T; Imura S; Morine Y; Ikemoto T; Arakawa Y; Iwahashi S; Saito YU; Takasu C; Ishikawa D; Teraoku H; Bando Y; Shimada M
    Anticancer Res; 2018 Jan; 38(1):501-507. PubMed ID: 29277815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
    Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V
    Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
    Lei J; Zhong J; Hao J; Liu Z; Zhang P; Wu L; Yan L; Zhu J; Zeng Y; Li B; Wen T; Wang W
    Oncotarget; 2016 Jul; 7(27):42598-42607. PubMed ID: 26981887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.